Halper Sadeh LLC Launches Shareholder Investigations for KNW, ELEV, and CRKN Halper Sadeh LLC is investigating Know Labs, Elevation Oncology, and Crown Electrokinetics regarding potential securities law breaches. This could impact shareholders significantly.

Halper Sadeh LLC Launches Shareholder Investigations for KNW, ELEV, and CRKN #United_States #New_York #Elevation_Oncology #Know_Labs #Crown_Electrokinetics

Halper Sadeh LLC Launches Investigation into FLS, KNW, ELEV, CRKN Shareholder Rights Halper Sadeh LLC is examining potential federal securities law violations by Flowserve, Know Labs, Elevation Oncology, and Crown Electrokinetics.

Halper Sadeh LLC Launches Investigation into FLS, KNW, ELEV, CRKN Shareholder Rights #United_States #New_York #Elevation_Oncology #Flowserve #Know_Labs

Elevation Oncology Announces Acquisition by Concentra Biosciences as New Era in Cancer Treatment Elevation Oncology has announced its merger with Concentra Biosciences, promising new developments in cancer therapies. This strategic move is expected to enhance shareholder value.

Elevation Oncology Announces Acquisition by Concentra Biosciences as New Era in Cancer Treatment #United_States #Boston #cancer_therapies #Elevation_Oncology #Concentra_Biosciences

Elevation Oncology Reveals First Quarter 2025 Financial Performance and Future Directions Elevation Oncology has shared its first quarter 2025 financial results, highlighting progress in HER3 ADC EO-1022 development and strategic options to enhance shareholder value.

Elevation Oncology Reveals First Quarter 2025 Financial Performance and Future Directions #USA #Boston #Elevation_Oncology #HER3_ADC #EO-1022

Elevation Oncology Unveils Promising EO-1022 Data at AACR Annual Meeting 2025 Elevation Oncology shared compelling preclinical data for EO-1022 at AACR 2025, showcasing its potential as a HER3 ADC in treating solid tumors.

Elevation Oncology Unveils Promising EO-1022 Data at AACR Annual Meeting 2025 #USA #Chicago #Elevation_Oncology #HER3_ADC #EO-1022

Elevation Oncology Shifts Focus from EO-3021 to EO-1022 Following Development Update Elevation Oncology announces the discontinuation of EO-3021 development while channeling efforts into EO-1022, as it evaluates strategic options for shareholder value.

Elevation Oncology Shifts Focus from EO-3021 to EO-1022 Following Development Update #USA #Boston #Elevation_Oncology #EO-3021 #EO-1022

Elevation Oncology Reveals Q4 and Full Year 2024 Financial Performance and Corporate Achievements Elevation Oncology announces significant financial outcomes for Q4 and the entirety of 2024, along with major achievements in its cancer treatment programs.

Elevation Oncology Reveals Q4 and Full Year 2024 Financial Performance and Corporate Achievements #United_States #Boston #Elevation_Oncology #EO-3021 #HER3_ADC

Elevation Oncology's Progress in Trailblazing ADC Treatments for Advanced Cancer Patients Elevation Oncology has made significant strides in its clinical trials for innovative ADC therapies aimed at treating advanced gastric cancer, with promising results expected soon.

Elevation Oncology's Progress in Trailblazing ADC Treatments for Advanced Cancer Patients #United_States #Boston #Elevation_Oncology #EO-3021 #ADCs

Elevation Oncology Accelerates Cancer Treatment Innovations with EO-1022, a New ADC Development Candidate Elevation Oncology has introduced EO-1022, a HER3 ADC aimed at treating solid tumors. This novel candidate showcases advanced technologies for potential cancer therapy breakthroughs.

Elevation Oncology Accelerates Cancer Treatment Innovations with EO-1022, a New ADC Development Candidate #United_States #Boston #Elevation_Oncology #HER3_ADC #EO-1022

Elevation Oncology Collaborates with Synaffix to Enhance ADC Drug Development Elevation Oncology has secured a licensing agreement with Synaffix for innovative ADC technology to boost their drug development pipeline targeting solid tumors.

Elevation Oncology Collaborates with Synaffix to Enhance ADC Drug Development #Netherlands #Amsterdam #ADC_technology #Synaffix #Elevation_Oncology

Elevation Oncology Reveals Promising EO-3021 Data at ESMO Immuno-Oncology Congress 2024 Elevation Oncology has presented preclinical data for EO-3021 demonstrating significant anti-tumor effects when combined with VEGFR2 or PD-1 inhibitors, promising new treatment avenues.

Elevation Oncology Reveals Promising EO-3021 Data at ESMO Immuno-Oncology Congress 2024 #United_States #cancer_therapy #Boston #Elevation_Oncology #EO-3021